AndreaBozzo/ceres-open-data-index huggingface dataset:
V-safe COVID-19

Users of the V-safe data are required to adhere to the following standards for the analysis and reporting of research data. All research results must be presented and/or published in a manner that protects the confidentiality of participants. V-safe data will not be presented and/or published in any way in which an individual can be identified. Therefore, users will:
<ol>
<li>Not attempt to link or permit others to link the data with individually identified records in another database.</li>
<li>Not attempt to learn the identity of any participant in the data and will not deliberately combine these data with other CDC or non-CDC data for the purpose of matching records to identify individuals. If you should inadvertently discover the identity of any participant, you will ensure the identity of any participant is kept confidential, and will not be used in any publications and/or presentations.</li>
<li>Not imply or state, either in written or oral form, that interpretations based on analysis of the data reflect official CDC policies or positions.</li>
<li>Understand that sub-national analyses are not appropriate for this national sample and will not be conducted. </li>
<li>Understand that V-safe is a voluntary self-enrollment program requiring smartphone access; therefore, information from V-safe might not be representative or generalizable to the US population.</li></ol>
By clicking on the weblink below to download and use these V-safe data, you signify your agreement to comply with the above-stated terms.

V-safe is a voluntary U.S. active safety surveillance system established by CDC to characterize local and systemic side effects of new vaccines administered after U.S. authorization or licensure. V-safe participants are not a random sample of all vaccinated persons in the United States and data might not be generalizable to the full U.S. vaccinated population. Participants may have been more likely to complete surveys if experiencing symptoms post-vaccination. All V-safe measures are self-reported, therefore there may be some misclassification of outcomes, vaccine-related information, or demographics.

For participants who requested corrections (i.e. vaccination date or vaccine manufacturer) to their vaccination record, data may be missing for one or more doses.  Requested corrections were applied to ‘Enrollment’, ‘Vaccination’, and ‘Dose History’ files. The old vaccination records are located in the ‘Vaccination (Old Records)’ file while the corrected vaccine records are in the ‘Vaccination’ file. Mobile outages or technical malfunctions may have caused a small number of missing surveys or collection of incorrect survey type. Occasional system outages and attrition over time also contribute to incomplete reporting. 

V-safe COVID-19 public data includes enrollment, vaccination information, and daily and weekly surveys collected from 1/22/2024 to 3/23/2025. Corresponding V-safe Registration public data (de-identified demographic data) can be downloaded at data.cdc.gov. Please review the V-safe data user agreement before analyzing any V-safe data.
Oxycodone and acetaminophen

Oxycodone and Acetaminophen is a prescription pain reliever combining an opioid (oxycodone) and a non-opioid (acetaminophen) to manage moderate to severe pain. Available as oral tablets in strengths like 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg, and 10mg/325mg oxycodone/acetaminophen. It's a DEA Schedule II controlled substance due to addiction risk. Manufactured by Lupin Pharmaceuticals, Inc. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E399791-T1: [Translated] PSEUDOPEPTIDES THAT STIMULATE THE SECRETION OF GROWTH HORMONE

The present invention relates to novel growth hormone releasing pseudopeptides capable of stimulating the release of growth hormone from the pituitary and of promoting growth in mammals. The invention also provides pharmaceutical compositions comprising the pseudopeptides growth hormone secretagogues and a method for promoting the release of growth hormone in mammals. If continuously administered, the present pseudopeptides may also inhibit the release of growth hormone by down-regulating the growth response. An exemplary pseudopeptide compound of this invention is Aib-D-Trp-D-Trppsi[CH2-NH-O]Gly-NH2 (IIa).
NNDSS - TABLE 1NN. Viral hemorrhagic fevers, Guanarito virus to Viral hemorrhagic fevers, Lassa virus

NNDSS - TABLE 1NN. Viral hemorrhagic fevers, Guanarito virus to Viral hemorrhagic fevers, Lassa virus – 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Compound 525688: Pentafluoropropionic acid, tetradecyl ester

Chemical compound data from PubChem database. IUPAC Name: tetradecyl 2,2,3,3,3-pentafluoropropanoate. Molecular Formula: C17H29F5O2. Molecular Weight: 360.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526084: 3,11,21-Tris[(trimethylsilyl)oxy]pregnan-20-one

Chemical compound data from PubChem database. IUPAC Name: 1-[10,13-dimethyl-3,11-bis(trimethylsilyloxy)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-trimethylsilyloxyethanone. Molecular Formula: C30H58O4Si3. Molecular Weight: 567.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530590: 2-Bromopropionic acid, tridecyl ester

Chemical compound data from PubChem database. IUPAC Name: tridecyl 2-bromopropanoate. Molecular Formula: C16H31BrO2. Molecular Weight: 335.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011 CMHS Uniform Reporting System (URS) Output Tables for Mississippi

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
2010-2012 NSDUH Guide to Substate Tables and Summary of Small Area Estimation Methodology

This report discusses the methodology used in the 2010 to 2012 National Survey on Drug Use and Health (NSDUH) report that assesses past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older by 362 substate regions within the 50 States and the District of Columbia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Compound 525488: 3-(Methylsulfanyl)propane-1-thiol

Chemical compound data from PubChem database. IUPAC Name: 3-methylsulfanylpropane-1-thiol. Molecular Formula: C4H10S2. Molecular Weight: 122.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Plan Attributes PUF - PY2014

The Plan Attributes PUF (Plan-PUF) is one of the seven files that make up the Marketplace PUF. The Plan-PUF contains plan-level data on maximum out of pocket payments, deductibles, cost sharing, health savings account (HSA) eligibility, formulary ID, and other plan attributes. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated). The issuer can also import data created in other templates (e.g., Network IDs from the Network ID template, Service Area IDs from the Service Area template, and Formulary IDs from the Prescription Drug template) to use as allowable values for the applicable fields in the Plans &amp; Benefits template, or enter these values manually.
Tetraethylammonium block of water flux in Aquaporin-1 channels expressed in kidney thin limbs of Henle's loop and a kidney-derived cell line.

Background
          Aquaporin-1 (AQP1) channels are constitutively active water channels that allow rapid transmembrane osmotic water flux, and also serve as cyclic-GMP-gated ion channels. Tetraethylammonium chloride (TEA; 0.05 to 10 mM) was shown previously to inhibit the osmotic water permeability of human AQP1 channels expressed in Xenopus oocytes. The purpose of the present study was to determine if TEA blocks osmotic water flux of native AQP1 channels in kidney, and recombinant AQP1 channels expressed in a kidney derived MDCK cell line. We also demonstrate that TEA does not inhibit the cGMP-dependent ionic conductance of AQP1 expressed in oocytes, supporting the idea that water and ion fluxes involve pharmacologically distinct pathways in the AQP1 tetrameric complex.
        
        
          Results
          TEA blocked water permeability of AQP1 channels in kidney and kidney-derived cells, demonstrating this effect is not limited to the oocyte expression system. Equivalent inhibition is seen in MDCK cells with viral-mediated AQP1 expression, and in rat renal descending thin limbs of Henle's loops which abundantly express native AQP1, but not in ascending thin limbs which do not express AQP1. External TEA (10 mM) does not block the cGMP-dependent AQP1 ionic conductance, measured by two-electrode voltage clamp after pre-incubation of oocytes in 8Br-cGMP (10–50 mM) or during application of the nitric oxide donor, sodium nitroprusside (2–4 mM).
        
        
          Conclusions
          TEA selectively inhibits osmotic water permeability through native and heterologously expressed AQP1 channels. The pathways for water and ions in AQP1 differ in pharmacological sensitivity to TEA, and are consistent with the idea of independent solute pathways within the channel structure. The results confirm the usefulness of TEA as a pharmacological tool for the analysis of AQP1 function.
Trends in Substance Use Disorders among Males Aged 18 to 49 on Probation or Parole

This National Survey on Drug Use and Health (NSDUH) short report looks at trends in substance use disorder (SUD) among males aged 18 to 49 on probation or parole during the past 12 months. The report looks those who had an alcohol or illicit drug use disorder, or both, in the past year.
Mental Health Client-Level Data (MH-CLD) 2022: Data On Clients Receiving Mental Health Treatment Services Through State Mental Health Agencies

This report describes the total number of clients receiving mental health treatment services in 2022 by demographics, National Outcome Measures (NOMs) and the top five mental health diagnoses for children (ages 0 - 17) and adults (18 and older) by geographical distribution. This report also includes client characteristics and the top 5 mental health diagnoses among all clients receiving mental health treatment services for the 2018-2022 MH-CLD reporting periods. The NOMs presented in this report include stability in housing/residential status, adult employment, and access to services/capacity.
Compound 525967: 2-(1-Methylpropyl)thiazolidine

Chemical compound data from PubChem database. IUPAC Name: 2-butan-2-yl-1,3-thiazolidine. Molecular Formula: C7H15NS. Molecular Weight: 145.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
QHP Landscape PY2024 Individual Dental

The Dental Individual Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to consumers in the individual market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Patent AT-E401094-T1: [Translated] USE OF A GINKGO EXTRACT TO TREAT CANCER CHARACTERIZED BY OVEREXPRESSION OF PERIPHERAL BENZODIAZEPINE RECEPTOR PROTEIN

The present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated Ginkgolide B (GKB), a component of the extract of Ginkgo biloba leaves in a method for decreasing the expression of peripheral-type benzodiazepine receptor (PBR) in cells of a patient in need thereof. Further, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method for decreasing the proliferation of cancer cells in a patient. More particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in a method of decreasing cancer cell proliferation in a patient wherein the cancer cell is human breast cancer cell. Even more particularly, the present invention is directed to the use of the extract of Ginkgo biloba leaves or isolated GKB in method of decreasing cancer cell proliferation in a patient wherein the cancer cell is of the aggressive and invasive phenotype and expresses high levels of PBR in comparison to non-aggressive cancer cell.
Title IV-E Development Grants

Standing Announcement for Tribal Title IV-E Plan Development Grants - These grants are funded via a standing funding opportunity announcement (SFOA), which means that the same announcement (with minor modifications) is published each year. To view published and archived SFOAs, visit Grants.gov
  
  

. Each year a new group of Tribal Title IV-E Plan Development grants is awarded. Information about which applicants received awards can be found on the Children's Bureau website.

The purpose of the Standing Announcement for Tribal Title IV-E Plan Development Grants is to make one-time grants to tribes, tribal organizations, or tribal consortia that are seeking to develop and, within 24 months of grant receipt, submit to the U.S. Department of Health and Human Services a plan to implement a title IV-E foster care, adoption assistance, and, at tribal option, guardianship assistance program. Grant funds under this announcement may be used for the cost of developing a title IV-E plan under section 471 of the Social Security Act (the Act) to carry out a program under section 479B of the Act. The grant may be used for costs relating to the development of data-collection systems, a cost-allocation methodology, agency and tribal court procedures necessary to meet the case-review system requirements under Section 475(5) of the Act, or any other costs attributable to meeting any other requirement necessary for approval of a title IV-E plan.

Metadata-only record linking to the original dataset. Open original dataset below.
National Directory of Drug and Alcohol Abuse Treatment Facilities 2014

The National Directory of Drug and Alcohol Abuse Treatment Programs 2014 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 2013 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 2013 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
QHP Landscape PY2023 Individual Dental

The Dental Individual Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to consumers in the individual market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Title IV-E Reviews — Peer Reviewer Qualifications

The Children’s Bureau conducts the Title IV-E Foster Care Eligibility Reviews (IV-E Reviews) to monitor Title IV-E agencies’ compliance with federally mandated requirements under Title IV, Part E, of the Social Security Act. To that end, a IV-E Review team, which may include Peer Reviewers, conducts case record reviews using the Title IV-E Foster Care Eligibility On-Site Review Instrument and Instructions. (Peer Reviewers are not used for every IV-E Review. The Children's Bureau may use up to two Peer Reviewers for a primary review and up to four Peer Reviewers for a secondary review.)

Peer Reviewers are Title IV-E experts who can make individual professional judgments regarding initial and ongoing eligibility for Title IV-E programs. They perform this work as participants in the IV-E Reviews. Peer Reviewers must have extensive knowledge of Title IV-E eligibility criteria. The qualifications for individuals interested in participating as Peer Reviewers include:

We encourage applications from bilingual and Spanish-speaking persons, and those with experience working in Tribal child welfare programs.

For more information on becoming a Peer Reviewer in the IV-E Reviews, please contact the Child Welfare Compliance Reviews Team at JBS International, Inc. (See Title IV-E Foster Care Eligibility Reviews Peer Reviewer Information page to contact)

Metadata-only record linking to the original dataset. Open original dataset below.
Business Rules PUF - PY2015

The Business Rules PUF (BR-PUF) is one of the seven files that make up the Marketplace PUF. The BR-PUF contains plan-level data on the application of rates, such as allowed relationships (e.g., spouse, dependents) and tobacco use. These data either originate from the Business Rules template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Compound 525481: 4-Methyl-3-thia-1-pentanethiol

Chemical compound data from PubChem database. IUPAC Name: 2-propan-2-ylsulfanylethanethiol. Molecular Formula: C5H12S2. Molecular Weight: 136.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525586: N,N-Dimethyl-N'-(4-bromophenyl)-benzamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-bromophenyl)-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C15H15BrN2. Molecular Weight: 303.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528150: 5-Sec-butyl-3-methyl-2-(phenylthio)pyrazine

Chemical compound data from PubChem database. IUPAC Name: 5-butan-2-yl-3-methyl-2-phenylsulfanylpyrazine. Molecular Formula: C15H18N2S. Molecular Weight: 258.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Prevalence of Hearing Loss in the United States by Industry, 2000-2008

Background: Twenty-two million workers are exposed to hazardous noise in the United States. The purpose of this study is to estimate the prevalence of hearing loss among U.S. industries.

Methods: We examined 2000–2008 audiograms for male and female workers ages 18–65, who had higher occupational noise exposures than the general population. Prevalence and adjusted prevalence ratios (PRs) for hearing loss were estimated and compared across industries.

Results: In our sample, 18% of workers had hearing loss. When compared with the Couriers and Messengers industry sub-sector, workers employed in Mining (PR = 1.65, CI = 1.57–1.73), Wood Product Manufacturing (PR = 1.65, CL = 1.61– 1.70), Construction of Buildings (PR = 1.59, CI = 1.51–1.68), and Real Estate and Rental and Leasing (PR = 1.61, CL = 1.51–1.71) had higher risks for hearing loss.

Conclusions: Workers in the Mining, Manufacturing, and Construction industries need better engineering controls for noise and stronger hearing conservation strategies. More hearing loss research is also needed within traditional ‘‘low-risk’’ industries like Real Estate.
Compound 527976: 1,2-Cyclohexanedicarboxylic acid, 4-methyl, dimethyl ester

Chemical compound data from PubChem database. IUPAC Name: dimethyl 4-methylcyclohexane-1,2-dicarboxylate. Molecular Formula: C11H18O4. Molecular Weight: 214.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.